ClearPoint Neuro Inc vs Tidewater Inc — how do they compare? ClearPoint Neuro Inc trades at $15.01 (market cap $454.21M), while Tidewater Inc trades at $92.09 (market cap $4.54B). The key difference: Tidewater Inc is far larger — about 10× ClearPoint Neuro Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | TDW | |
|---|---|---|
Market Cap | $454.21M | $4.54B |
Sector | Health | Utilities |
52-Week High | $29.60 | $91.20 |
52-Week Low | $8.66 | $47.29 |
Enterprise Value | $488.79M | $4.58B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Tidewater (TDW) trades at $90.20, up 0.64% today, with a bullish technical signal driven by moving averages and ADX. Recent Q2 2026 earnings beat estimates (EPS $0.43 vs. $0.32 expected, Zacks Investment Research, 2026-08-03), though quarterly EPS has missed expectations in three of the last four quarters. The company maintains strong profitability with an 18.34% net margin and robust cash flow from operations of $379.11 million in 2025.
Outlook is mixed: bullish technicals and institutional interest support upside, but earnings misses and a high RSI near overbought levels pose risks. Analyst consensus leans hold (57.7%), with valuation metrics like P/E of 18.5 suggesting fair pricing. Key risks include operational costs from Middle East conflicts and revenue volatility.
Trailing returns across standard periods
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →